Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE - PUMA BIOTECHNOLOGY, INC. | d260222dex991.htm |
EX-10.2 - AMENDMENT NO. 1-REGISTRATION RIGHTS AGREEMENT - PUMA BIOTECHNOLOGY, INC. | d260222dex102.htm |
EX-10.1 - FORM OF SUBSCRIPTION AGREEMENT - PUMA BIOTECHNOLOGY, INC. | d260222dex101.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): November 18, 2011
PUMA BIOTECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Delaware | 000-52811 | 77-0683487 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
10940 Wilshire Blvd, Suite 600
Los Angeles, CA 90024
(Address of principal executive offices) (Zip Code)
(310) 443-4150
(Registrants telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 | Entry Into A Material Definitive Agreement. |
On November 18, 2011, Puma Biotechnology, Inc., a Delaware corporation (the Company), entered into subscription agreements (the Subscription Agreements) with certain accredited investors (the Investors), including Thomas R. Malley, a director of the Company, pursuant to which the Company sold in a private placement (the Offering) an aggregate of 1,333,267 shares of the Companys common stock, par value $0.0001 per share (the Shares), at a price per share of $3.75. The Company received aggregate gross proceeds of approximately $5.0 million from the sale of the Shares.
Leerink Swann LLC acted as lead placement agent and National Securities Corporation acted as co-placement agent in connection with the Offering and received compensation of approximately $84,000 and $150,000, respectively. A copy of the press release announcing the Offering is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.
Also on November 18, 2011, the Company entered into Amendment No. 1 (the Amendment) to that certain Registration Rights Agreement, dated as of October 4, 2011 (the Registration Rights Agreement), among the Company and the stockholders listed therein. The Amendment amended the Registration Rights Agreement to permit the inclusion of the Investors as parties thereto. In connection with the Offering, each Investor became a party to the Registration Rights Agreement and the Company became obligated to register for resale the Shares held by such Investor pursuant to the terms of the Registration Rights Agreement. The material terms of the Registration Rights Agreement are described in the Companys Current Report on Form 8-K filed with the Securities and Exchange Commission on October 11, 2011.
The foregoing descriptions of the Subscription Agreements and the Amendment are qualified in their entirety by reference to the full text of the form of Subscription Agreement and the Amendment, copies of which are filed as Exhibits 10.1 and 10.2 hereto, respectively, and are incorporated herein by reference.
Item 3.02 | Unregistered Sales of Equity Securities. |
The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02. The offering and sale of the Shares were exempt from registration under Section 4(2) of the Securities Act of 1933, as amended (the Securities Act), and Rule 506 of Regulation D promulgated thereunder. The Shares have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements. The sale of the securities did not involve a public offering and was made without general solicitation or general advertising. The Investors represented that they are accredited investors, as such term is defined in Rule 501(a) of Regulation D under the Securities Act and that they acquired the securities for investment purposes only and not with a view to any resale, distribution or other disposition of the Shares in violation of the United States federal securities laws.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
10.1 | Form of Subscription Agreement | |
10.2 | Amendment No. 1 to Registration Rights Agreement, dated November 18, 2011, by and among the Company and the persons party thereto | |
99.1 | Press Release dated November 23, 2011 |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PUMA BIOTECHNOLOGY, INC. | ||||||
Date: November 23, 2011 | By: | /s/ Alan H. Auerbach | ||||
Alan H. Auerbach | ||||||
Chief Executive Officer and President |
EXHIBIT INDEX
Exhibit |
Description | |
10.1 | Form of Subscription Agreement | |
10.2 | Amendment No. 1 to Registration Rights Agreement, dated November 18, 2011, by and among the Company and the persons party thereto | |
99.1 | Press Release dated November 23, 2011 |